Researchers found that seven days of antibiotics is likely noninferior to 14 days for Gram-negative bloodstream infections, supporting shorter treatment durations.
Sipavibart reduced symptomatic COVID-19 by 34.9% compared to standard treatment, but efficacy was only observed against non–Phe456Leu-containing variants, according to new phase 3 trial data.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.